EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances in the Pathogenesis and Treatment of Systemic Lupus Erythematosus

Daniele Accapezzato iD, Rosalba Caccavale, Maria Pia Paroli iD, Chiara Gioia iD, Bich Lien Nguyen, Luca Spadea, Marino Paroli iD

International Journal of Molecular Sciences · 31.03.2023 · 24 (7) · 6578

DOI: 10.3390/ijms24076578 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 31.03.2023. Verfasst von Daniele Accapezzato und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Immunology, Department of Clinical, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy. Hauptthemen laut MEDLINE: Adaptive Immunity, Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 136-mal zitiert (Crossref) und nennt 213 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic lupus erythematosus (SLE) is a genetically predisposed, female-predominant disease, characterized by multiple organ damage, that in its most severe forms can be life-threatening. The pathogenesis of SLE is complex and involves cells of both innate and adaptive immunity. The distinguishing feature of SLE is the production of autoantibodies, with the formation of immune complexes that precipitate at the vascular level, causing organ damage. Although progress in understanding the pathogenesis of SLE has been slower than in other rheumatic diseases, new knowledge has recently led to the development of effective targeted therapies, that hold out hope for personalized therapy. However, the new drugs available to date are still an adjunct to conventional therapy, which is known to be toxic in the short and long term. The purpose of this review is to summarize recent advances in understanding the pathogenesis of the disease and discuss the results obtained from the use of new targeted drugs, with a look at future therapies that may be used in the absence of the current standard of care or may even cure this serious systemic autoimmune disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adaptive ImmunityLupus Erythematosus, SystemicFemaleHumansAutoantibodiesAntigen-Antibody Complex

Stichwörter der Autor:innen

B-cellsT-cellscell-based therapyplasmacytoid cellssystemic lupus erythematosustype-I interferon

Substanzen

AutoantibodiesAntigen-Antibody Complex

Autor:innen und Institutionen

  • Division of Clinical Immunology, Department of Clinical, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy.
  • Eye Clinic, Department of Sense Organs, Sapienza University of Rome, 00185 Rome, Italy.
  • Post Graduate School of Public Health, University of Siena, 53100 Siena, Italy.

ORCID-Profile: Daniele Accapezzato, Maria Pia Paroli, Chiara Gioia, Marino Paroli

Zitieren

APA

Accapezzato, D., Caccavale, R., Paroli, M. P., Gioia, C., Nguyen, B. L., Spadea, L., & Paroli, M. (2023). Advances in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. International Journal of Molecular Sciences, 24(7), 6578. https://doi.org/10.3390/ijms24076578

Vancouver

Accapezzato D, Caccavale R, Paroli MP, Gioia C, Nguyen BL, Spadea L, et al. Advances in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. International Journal of Molecular Sciences. 2023;24(7):6578. doi:10.3390/ijms24076578

BibTeX
@article{Accapezzato2023,
  author = {Accapezzato, Daniele and Caccavale, Rosalba and Paroli, Maria Pia and Gioia, Chiara and Nguyen, Bich Lien and Spadea, Luca and Paroli, Marino},
  title = {Advances in the Pathogenesis and Treatment of Systemic Lupus Erythematosus},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {7},
  pages = {6578},
  doi = {10.3390/ijms24076578}
}
Kostenlos starten →